Jan 12 (Reuters) - Swiss drugmaker Novartis has signed a licensing deal worth nearly $1.7 billion with privately held SciNeuro Pharmaceuticals to develop potential antibody treatments for Alzheimer's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results